bioAffinity Technologies (BIAF) Net Cash Flow (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Net Cash Flow data on file, last reported at -$3.4 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$3.4 million, down 407.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 million (up 232.12% YoY), and the FY2025 annual result was $5.3 million, up 411.4% from the prior year.
• Net Cash Flow declined to -$3.4 million in Q1 2026 per BIAF's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $13.3 million in Q3 2022 and troughed at -$3.8 million in Q3 2023.
• A 5-year average of $115159.7 and a median of -$813630.0 in 2022 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 15450.34% in 2025 and fell as far as 449.69% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$1.9 million in 2022, then climbed by 9.47% to -$1.7 million in 2023, then soared by 120.66% to $348711.0 in 2024, then plunged by 449.69% to -$1.2 million in 2025, then tumbled by 174.84% to -$3.4 million in 2026.
• Business Quant data shows BIAF's Net Cash Flow at -$3.4 million in Q1 2026, -$1.2 million in Q4 2025, and $6.9 million in Q3 2025.